ObelysQ is a clinical quality and compliance consulting firm founded in 2020 and based in Neuchâtel, Switzerland. Its clients include biotech companies, pharmaceutical companies, CROs, and clinical research centers. It is worth noting that the crawled content does not present ObelysQ as a standard SaaS platform; it looks more like a professional services company, with its core value centered on experienced GCP/GxP quality assurance consultants and inspection support.
Its services cover QA consulting, GxP auditing, QMS/SOP development, Inspection Management, Training, Gap Analysis, and Data Protection Support. The content repeatedly emphasizes a risk-based approach, a regulatory perspective, and practical execution in clinical trial settings—for example, acting as a GCP Quality Lead for small biotech companies, conducting GVP/GCP audits, helping build lightweight QMS frameworks, drafting or integrating SOPs, and supporting regulatory inspections by EMA, FDA, MHRA, Swissmedic, and other authorities. On data compliance, ObelysQ provides GDPR gap analysis, external DPO services, EU data representative support, and assistance with informed consent, data transfer agreements, access controls, and records of processing activities.
The website does not disclose packages, pricing, payment methods, or contract terms. Delivery appears flexible: support can be provided on-site, remotely, or in a hybrid format, and can also be arranged to fill client resource gaps on a basis such as “two days per week,” “several days per month,” or short-term intensive support. Before purchasing, buyers will need to use the contact form to discuss scope, consultant seniority, deliverables, and pricing.
Its strengths are its focused domain expertise and an end-to-end service chain around clinical quality, audits, inspection readiness, and CAPA remediation. The case examples span cross-regional projects in Europe, the United States, Latin America, Asia, and elsewhere, and multilingual inspection support is also mentioned. It is especially valuable for early-stage biotech companies lacking internal QA resources. The limitations are also clear: there is no visible information on account systems, permissions, automated workflows, third-party integrations, APIs, or cloud/self-hosted deployment. If a company is looking for QMS software, eTMF, CTMS, or training management SaaS, the available text does not show that ObelysQ itself can replace those systems.
ObelysQ is suitable for life sciences teams that need clinical GCP/GxP compliance experts, regulatory inspection readiness, QMS/SOP development, audit outsourcing, or GDPR-related clinical data protection support. Access from mainland China, payment methods, and local invoice support are not disclosed, so china_access can only be assessed as unknown. If a China-based team needs localized implementation, it may also evaluate domestic CRO quality and compliance service providers, pharmaceutical consulting firms, or separately procure local QMS/CTMS/eTMF software as an alternative or complement.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on obelysq.com official site.
obelysq.com is an Switzerland SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach obelysq.com directly.